Company Overview

Embecta Corp. is a global medical device company focused exclusively on diabetes care, with a primary emphasis on insulin delivery solutions. The company operates within the medical devices and healthcare supplies industry, serving patients who require daily insulin injections. Its core products include insulin syringes, pen needles, and safety-engineered injection devices, which together represent the majority of its revenue. Embecta primarily serves hospitals, clinics, pharmacies, and patients through healthcare providers, with a strong presence in both developed and emerging markets.

Embecta was formed as an independent public company in April 2022 following its spin-off from Becton, Dickinson and Company (BD), where the business had operated for decades as BD’s Diabetes Care unit. The company positions itself around scale, long-standing customer relationships, and deep expertise in high-volume insulin delivery manufacturing. Its strategic advantage lies in its global manufacturing footprint, established distribution channels, and entrenched role in the daily treatment routines of insulin-dependent patients.

Business Operations

Embecta operates primarily through a single reporting segment focused on Diabetes Care, encompassing insulin syringes, pen needles, and related injection devices. Revenue is generated through high-volume, recurring sales of consumable medical devices, with demand driven by the global prevalence of diabetes and ongoing insulin therapy needs. The company’s portfolio includes both branded and private-label products sold to healthcare systems and distributors.

Operations are supported by a vertically integrated manufacturing and supply chain infrastructure, including proprietary production technologies for precision needles and safety devices. Embecta maintains manufacturing facilities across multiple regions and sells products in more than 100 countries. While the company does not currently report multiple operating segments, it continues to invest in device enhancements and adjacent technologies intended to improve patient safety, dosing accuracy, and ease of use.

Strategic Position & Investments

Embecta’s strategic direction centers on stabilizing and growing its core insulin delivery franchise while selectively investing in adjacent diabetes technologies. Growth initiatives include geographic expansion in underpenetrated markets, product line extensions within pen needles and safety-engineered devices, and operational efficiency programs following the separation from BD. The company has emphasized disciplined capital allocation, focusing on sustaining cash flow and reducing separation-related costs.

In addition to its core business, Embecta has disclosed investments in early-stage technologies related to drug delivery and diabetes management, though these initiatives currently represent a small portion of overall operations. As of available public disclosures, the company has not completed any transformative acquisitions since becoming independent. Data inconclusive based on available public sources regarding material joint ventures or large-scale platform acquisitions.

Geographic Footprint

Embecta is headquartered in the United States, with its principal executive offices located in New Jersey. The company maintains a broad international footprint, with manufacturing and distribution operations across North America, Europe, Asia, Latin America, and Emerging Markets. International sales represent a substantial portion of total revenue, reflecting the global nature of insulin-dependent diabetes care.

The company benefits from long-standing commercial relationships in both mature healthcare systems and rapidly growing markets, particularly in regions with rising diabetes prevalence. Embecta’s global scale enables it to serve multinational healthcare customers while adapting product offerings to local regulatory and clinical requirements.

Leadership & Governance

Embecta is led by an executive team with extensive experience in medical devices, operations, and global healthcare markets. The leadership emphasizes operational discipline, product reliability, and continuity for customers following the company’s separation from BD, while pursuing measured innovation within its core therapeutic focus.

Key executives include:

• Devdatt “Dev” Kurdikar – President and Chief Executive Officer
• Jake Elguicze – Chief Financial Officer
• Steve Mott – President, Diabetes Care
• Tim M. Baxter – Senior Vice President, Strategy and Corporate Development
• Holly Birmingham – Senior Vice President, Global Human Resources

The board and management team collectively emphasize patient safety, regulatory compliance, and long-term value creation, with governance practices aligned to U.S. public company standards following the spin-off.